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Croatian Society of Oncology and Radiothera-
py, Croatian Medical Association, organized the 
symposium on Immunotherapy of Solid Tumors, 
March 23, 2017, Zagreb, Croatia. The symposium 
was designed to provide state-of-the-art informa-
tions on this topic and was primarily directed to-
ward oncologists as well as other appropriate health 
care professionals. We are greatful to all speakers of 
this symposium for preparing their presentation as 
an article in this issue (Articles 1-10).
We oncologists take active part in the treat-
ment of patients with malignant tumours on a 
daily basis. However, in spite of the obvious ad-
vancements that medicine has made in the past 
decades, we are still faced with a signifi cant num-
ber of patients with the disseminated malignant 
disease that cannot be treated successfully by the 
standard mode of treatment.
This is the reason why, like all the other on-
cologists in the world, we are impressed by the 
successes achieved with the application of immu-
notherapy in the treatment of tumours, which has 
been gaining ground these past years. Immuno-
therapy is a kind of treatment which has been ex-
plored for decades and which has been showing 
great potential to become a new method of treat-
ment. Nevertheless, it has taken the advancements 
and breakthroughs in molecular biology to really 
push immunotherapy to the forefront of the new-
est medical achievements and make it the method 
of choice.
Nowadays, immunotherapy has become an 
integral part of the treatment of numerous tu-
mours in the advanced stages of the disease and it 
is used in most of the countries belonging to the 
developed world. In Croatia, however, it is only 
recently that we are seeing the beginnings of avail-
ability of such treatments for our patients.
The intention behind this issue is to inform 
the oncologists about the following: up-to-date 
achievements with the application of immuno-
therapy in the treatment of solid tumours; current 
research taking place in the fi eld; the way immu-
notherapy aﬀ ects the disease; an assessment of the 
response to this specifi c way of treatment; the pos-
sible negative side-eﬀ ects of the therapy and the 
ways in which they could be treated; the eﬀ ect of 
radiation therapy on immunotherapy, as well as 
the possibility of predicting the response to the 
therapy on the basis of new biomarkers.
